{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T08:35:42Z","timestamp":1774686942184,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":1126,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1097\/jto.0b013e318267cf84","type":"journal-article","created":{"date-parts":[[2012,10,11]],"date-time":"2012-10-11T14:20:46Z","timestamp":1349965246000},"page":"1713-1721","source":"Crossref","is-referenced-by-count":46,"title":["Safety, Resource Use, and Quality of Life in Paramount: A Phase III Study of Maintenance Pemetrexed Versus Placebo after Induction Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non\u2013Small-Cell Lung Cancer"],"prefix":"10.1016","volume":"7","author":[{"given":"Cesare","family":"Gridelli","sequence":"first","affiliation":[]},{"given":"Filippo","family":"de Marinis","sequence":"additional","affiliation":[]},{"given":"Jean-Louis","family":"Pujol","sequence":"additional","affiliation":[]},{"given":"Martin","family":"Reck","sequence":"additional","affiliation":[]},{"given":"Rodryg","family":"Ramlau","sequence":"additional","affiliation":[]},{"given":"Barbara","family":"Parente","sequence":"additional","affiliation":[]},{"given":"Thierry","family":"Pieters","sequence":"additional","affiliation":[]},{"given":"Gary","family":"Middleton","sequence":"additional","affiliation":[]},{"given":"Jesus","family":"Corral","sequence":"additional","affiliation":[]},{"given":"Katherine","family":"Winfree","sequence":"additional","affiliation":[]},{"given":"Symantha","family":"Melemed","sequence":"additional","affiliation":[]},{"given":"Anna","family":"Zimmermann","sequence":"additional","affiliation":[]},{"given":"William","family":"John","sequence":"additional","affiliation":[]},{"given":"Julie","family":"Beyrer","sequence":"additional","affiliation":[]},{"given":"Nadia","family":"Chouaki","sequence":"additional","affiliation":[]},{"given":"Carla","family":"Visseren-Grul","sequence":"additional","affiliation":[]},{"given":"Luis G.","family":"Paz-Ares","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e318267cf84_bib1","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1200\/JCO.2010.34.2774","article-title":"2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer","volume":"29","author":"Azzoli","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318267cf84_bib2","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2008.17.1405","article-title":"Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer","volume":"27","author":"Fidias","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318267cf84_bib3","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(09)61497-5","article-title":"Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study","volume":"374","author":"Ciuleanu","year":"2009","journal-title":"Lancet"},{"key":"10.1097\/JTO.0b013e318267cf84_bib4","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(10)70112-1","article-title":"Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study","volume":"11","author":"Cappuzzo","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1097\/JTO.0b013e318267cf84_bib5","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/bmj.317.7161.771","article-title":"Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews","volume":"317","author":"Silvestri","year":"1998","journal-title":"BMJ"},{"key":"10.1097\/JTO.0b013e318267cf84_bib6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3816\/CLC.2009.n.010","article-title":"Importance of quality of life in patients with non-small-cell lung cancer","volume":"10","author":"Camps","year":"2009","journal-title":"Clin Lung Cancer"},{"key":"10.1097\/JTO.0b013e318267cf84_bib7","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318267cf84_bib8","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318267cf84_bib9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/JTO.0b013e31815e8b48","article-title":"Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer","volume":"3","author":"de Marinis","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e318267cf84_bib10","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1470-2045(11)70339-4","article-title":"Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study","volume":"13","author":"Belani","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1097\/JTO.0b013e318267cf84_bib11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(12)70063-3","volume":"13","author":"Paz-Ares","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1097\/JTO.0b013e318267cf84_bib12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2014a new facility for the measurement of health-related quality of life","volume":"16","author":"The EuroQol Group","year":"1990","journal-title":"Health Policy"},{"key":"10.1097\/JTO.0b013e318267cf84_bib13","series-title":"Lung AJCC Cancer Staging Manual","first-page":"127","author":"Fleming","year":"1997"},{"key":"10.1097\/JTO.0b013e318267cf84_bib14","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318267cf84_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1097\/JTO.0b013e318267cf84_bib17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00005650-200503000-00003","article-title":"US valuation of the EQ-5D health states: development and testing of the D1 valuation model","volume":"43","author":"Shaw","year":"2005","journal-title":"Med Care"},{"key":"10.1097\/JTO.0b013e318267cf84_bib18","series-title":"EQ-5D-3L User Guide: Basic information on how to use the EQ-5D-3L instrument. April 2011Version 4.0","author":"Rabin","year":"2011"},{"key":"10.1097\/JTO.0b013e318267cf84_bib19","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"key":"10.1097\/JTO.0b013e318267cf84_bib20","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/00019053-200725050-00002","article-title":"Health utilities using the EQ-5D in studies of cancer","volume":"25","author":"Pickard","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1097\/JTO.0b013e318267cf84_bib21","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1097\/JTO.0b013e31822e722f","article-title":"Skin toxicities compromise prolonged pemetrexed treatment","volume":"6","author":"Eguia","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e318267cf84_bib22","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1053\/j.ajkd.2011.04.030","article-title":"Kidney tubular toxicity of maintenance pemetrexed therapy","volume":"58","author":"Glezerman","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1097\/JTO.0b013e318267cf84_bib23","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1524-4733.2006.00108.x","article-title":"Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population","volume":"9","author":"Bharmal","year":"2006","journal-title":"Value Health"},{"key":"10.1097\/JTO.0b013e318267cf84_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10198-008-0097-2","article-title":"SF-6D versus EQ-5D: reasons for differences in utility scores and impact on reported cost-utility","volume":"10","author":"Grieve","year":"2009","journal-title":"Eur J Health Econ"},{"issue":"Suppl 1","key":"10.1097\/JTO.0b013e318267cf84_bib25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.12-S1-4","article-title":"Cancer-related fatigue: the scale of the problem","volume":"12","author":"Hofman","year":"2007","journal-title":"Oncologist"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415331439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415331439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T06:59:12Z","timestamp":1542697152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415331439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S1556086415331439"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e318267cf84","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}